-
A Phase 1/2 Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination with Other Anti-Cancer Therapies in Patients with KRAS BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies
This is a Phase 1/2 study testing a new oral cancer drug called S241656 (BDTX-4933 - an investigational anti-cancer drug) in patients whose cancers have ...
-
Phase 1/2a Open-Label Clinical Trial Evaluating VBC101 An EGFR And CMet Targeted Bi-Specific Antibody Drug Conjugate In Participants with Advanced Solid Tumor Malignancies
This is a multicenter, open-label, multiple-dose, FIH Phase 1/2a trial to evaluate the safety and tolerability of VBC101 and To determine the MTD and ... -
A Phase 1a/1b Study of LY4052031 an Antibody-Drug Conjugate Targeting Nectin-4 in Participants with Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors
This is a Phase 1a/1b study testing a new drug called LY4052031 (an experimental cancer drug) in patients with advanced cancers, including bladder (urothelial ...
-
A PHASE Ib/II OPEN-LABEL MULTICENTER RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE TREATMENT COMBINATIONS IN PATIENTS WITH METASTATIC BREAST CANCER (MORPHEUS-panBC)
This is a Phase 1b/2 clinical study for people with metastatic (which is breast cancer that has spread to other parts of the body ...
-
HYPO2-BOOST GBM trial: Hypoxia-targeted radiotherapy boost for GBM
This is a Phase 1/2 study that will be testing whether a special MRI scan, called dynamic contrast-enhanced MRI (DSC-MRI), can help doctors find ...
-
A Modular Phase I/II Open-label Multicentre Study to Evaluate the Safety Tolerability and Efficacy of AZD3470 a PRMT5 Inhibitor as Monotherapy and in Combination With Anticancer Agent(s) in Participants With Relapsed/Refractory Haematologic Malignancies
This is a Phase I/II, open-label, multicentre clinical study that is testing AZD3470, an investigational oral medicine, in people with blood cancers (haematologic malignancies ...